CAMBRIDGE, Mass., March 1, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has elected Thomas R. Hodgson, a current member and Lead Director of Idenix's Board and former President and Chief Operating Officer of Abbott Laboratories, to serve as Chairman of the Board. Additionally, Idenix has appointed Michael S. Wyzga to its Board of Directors and he will serve as Chairman of the Audit Committee. Mr. Wyzga is currently President and Chief Executive Officer of Radius Health, Inc., a leading company developing a new generation of drug therapies for osteoporosis and women's health. Mr. Wyzga has more than 20 years of experience in the biotechnology and high-technology industries providing leadership in the areas of corporate finance, strategic planning and business development, most recently serving as Executive Vice President, Finance and Chief Financial Officer of Genzyme Corporation.
" Tom Hodgson has served on Idenix's Board for 10 years and he has made significant contributions to Idenix's progress during that time. I look forward to his continued guidance and leadership as Chairman," said Ron Renaud, President and Chief Executive Officer of Idenix.
Renaud continued, "We are also pleased to have Mike join the Idenix Board of Directors, bringing a depth of industry experience from his notable 13-year tenure with Genzyme. His financial leadership and strategic planning background will be a valuable asset to the Board as we continue to advance our pipeline of novel HCV drug candidates."
Prior to joining Radius, Mr. Wyzga was Executive Vice President, Finance and Chief Financial Officer of Genzyme until its acquisition by Sanofi in April 2011. Mr. Wyzga joined Genzyme in 1998 and held primary responsibility for the firm's financial management worldwide. He provided key leadership in the successful $20.1 billion sale of Genzyme to Sanofi, which was the second-largest acquisition in biotechnology history. Prior to joining Genzyme, Mr. Wyzga was Chief Financial Officer of Sovereign Hill Software. He previously served as Vice President of Finance and Chief Financial Officer of CacheLink Corporation, a client/service software company. Mr. Wyzga also held management positions at Lotus Development Corporation and Digital Equipment Corporation. He received an MBA from Providence College and a BS from Suffolk University.About IdenixIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical Company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with hepatitis C infection. For further information about Idenix, please refer to www.idenix.com.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV